Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates
- PMID: 1346169
- PMCID: PMC240804
- DOI: 10.1128/JVI.66.2.1016-1020.1992
Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates
Abstract
The nucleotide changes that result in two restriction endonuclease polymorphisms that differentiate wild-type varicella-zoster virus (VZV) from the vaccine strain were determined. Oligonucleotide primers that flank these sites were used to amplify the intervening sequences with the polymerase chain reaction to identify VZV DNA in clinical isolates. Restriction enzyme digestion of the amplification products distinguished vaccine and wild-type genomes from one another. This study confirms the feasibility of amplifying VZV sequences so that they may be detected in clinical specimens and provides a molecular epidemiological approach to strain identification of VZV in vesicular lesions.
Similar articles
-
An evaluation of single nucleotide polymorphisms used to differentiate vaccine and wild type strains of varicella-zoster virus.J Med Virol. 2005 Jan;75(1):174-80. doi: 10.1002/jmv.20253. J Med Virol. 2005. PMID: 15543576
-
New method of differentiating wild-type varicella-zoster virus (VZV) strains from Oka varicella vaccine strain by VZV ORF 6-based PCR and restriction fragment length polymorphism analysis.J Clin Virol. 2004 Feb;29(2):113-9. doi: 10.1016/s1386-6532(03)00112-4. J Clin Virol. 2004. PMID: 14747030
-
Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR.J Clin Microbiol. 2000 Sep;38(9):3156-60. doi: 10.1128/JCM.38.9.3156-3160.2000. J Clin Microbiol. 2000. PMID: 10970349 Free PMC article.
-
The safety profile of varicella vaccine: a 10-year review.J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. J Infect Dis. 2008. PMID: 18419392 Review.
-
Varicella vaccine: the American experience.J Infect Dis. 1992 Aug;166 Suppl 1:S63-8. doi: 10.1093/infdis/166.supplement_1.s63. J Infect Dis. 1992. PMID: 1320652 Review.
Cited by
-
Vaccination to prevent varicella and shingles.J Clin Pathol. 2001 Oct;54(10):743-7. doi: 10.1136/jcp.54.10.743. J Clin Pathol. 2001. PMID: 11577118 Free PMC article.
-
Perspectives on vaccines against varicella-zoster virus infections.Curr Top Microbiol Immunol. 2010;342:359-72. doi: 10.1007/82_2010_12. Curr Top Microbiol Immunol. 2010. PMID: 20232192 Free PMC article.
-
Envelopment of varicella-zoster virus: targeting of viral glycoproteins to the trans-Golgi network.J Virol. 1995 Dec;69(12):7951-9. doi: 10.1128/JVI.69.12.7951-7959.1995. J Virol. 1995. PMID: 7494308 Free PMC article.
-
A polymorphic region of the human cytomegalovirus genome encoding putative glycoproteins.Arch Virol. 1994;137(1-2):117-21. doi: 10.1007/BF01311177. Arch Virol. 1994. PMID: 7979984
-
Molecular epidemiology of varicella-zoster virus in East London, England, between 1971 and 1995.J Clin Microbiol. 1997 Nov;35(11):2807-9. doi: 10.1128/jcm.35.11.2807-2809.1997. J Clin Microbiol. 1997. PMID: 9350738 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources